MSP008-22
Triple‑negative breast cancer and other solid tumors
Phase 1Active
Key Facts
Indication
Triple‑negative breast cancer and other solid tumors
Phase
Phase 1
Status
Active
Company
About Sathgen Therapeutics
Innovative plant‑derived oncology and antiviral drug developer with a Phase I lead candidate.
View full company profile